Hengrui Medicine gains approval for multiple clinical trials

Jiangsu Hengrui Medicine (SSE:600276) and its subsidiaries, including Suzhou Shengdiya Biomedical and Shanghai Hengrui Pharmaceutical, announced that they've received clinical trial approval from the National Medical Products Administration (NMPA) for SHR2554 tablets and several injectable drugs: SHR-A1811, SHR-A2102, Aderbelimab, SHR-A1904, and SHR-1701. SHR2554 is a selective EZH2 inhibitor designed for solid tumor treatment, while SHR-A1811 targets HER2-expressing tumors. SHR-A2102 is an antibody-drug conjugate (ADC) targeting Nectin-4, and Aderbelimab is an anti-PD-L1 antibody for cancer immunotherapy. SHR-1701 is a bispecific antibody targeting PD-L1 and TGF-B RII. The company indicated it will move forward with these trials, but also cautioned investors regarding uncertainties in drug development and regulatory approval processes. As of now, Hengrui has invested CNY 17,908 million in SHR2554 development, CNY 117,007 million in SHR-A1811, and CNY 20,547 million in SHR-A2102 and CNY 88,654 in Aderbelimab. Finally, CNY 67,352 million have been invested in SHR-1701.